Tag

Treatment Resistant Depression

All articles tagged with #treatment resistant depression

health-and-medicine2 days ago•7 min saved

Mount Sinai Study Identifies Three Neural Pathways Critical for Deep Brain Stimulation Success in Depression

Researchers at Mount Sinai have identified three specific white matter pathways that are essential for long-term relief in patients with severe depression treated via deep brain stimulation (DBS). Published in the American Journal of Psychiatry, the study analyzed the largest multicohort group to date, including data from the BROADEN trial and the University of Toronto. The findings indicate that successful outcomes depend on stimulating the cingulum bundle, forceps minor, and medial uncinate fasciculus/ventral amygdalofugal pathway. Patients who failed to improve after two years consistently showed insufficient engagement of the left cingulum bundle. This suggests that precise, connectivity-based electrode placement is more critical than general anatomical positioning. The results support the use of individualized brain maps to guide surgical targeting, potentially improving the efficacy of this experimental therapy for those who do not respond to conventional treatments.

via Science Daily|

#brain-connectivity #clinical-trials #deep-brain-stimulation

health1 month ago•4 min saved

Humboldt County Adds TMS Therapy to Address Mental Health Gaps

Two providers in Humboldt County, California, have launched Transcranial Magnetic Stimulation (TMS) services to treat depression and anxiety locally. This move addresses a significant access gap, as patients previously had to travel hundreds of miles for treatment. The therapy, which uses magnetic fields to stimulate brain cells, is FDA-approved for major depressive disorder and offers an alternative for those unresponsive to medication.

via Lost Coast Outpost|

#health #humboldt-county #mental-health

health2 months ago•36 min saved

UK NHS trial shows promise of a single-dose psilocybin with therapy for hard-to-treat depression

A UK National Health Service–based phase 2 feasibility randomized trial tested a single 25‑mg dose of psilocybin with psychological support versus placebo in 60 adults with treatment‑resistant major depressive disorder. At three and six weeks, the psilocybin group showed large, clinically meaningful reductions on the MADRS compared with placebo (about a 10–13 point advantage) and higher response/remission rates, with improvements in anxiety and well‑being. Adverse events were mostly mild and not clearly linked to the drug, and blinding was imperfect, suggesting expectancy effects contributed to the outcome. Feasibility metrics (recruitment, retention, data completeness) were favorable, supporting larger efficacy trials and consideration of cost‑effectiveness in public healthcare. Overall, the study demonstrates the practicality of delivering psilocybin‑assisted therapy in NHS settings, while recognizing limitations that future trials should address.

via Nature|

#depression #health #nhs

business3 months ago•10 min saved

Lilly’s $3.8B bet signals a new era for psychedelic mental-health drugs

Eli Lilly agreed to acquire AtaiBeckley for up to $3.8 billion, signaling Big Pharma’s embrace of psychedelic therapies such as BPL-003 (a synthetic 5-MeO-DMT nasal spray) for treatment-resistant depression, currently in Phase 3 with potential multi-billion-dollar returns. The broader field spans LSD, psilocybin, MDMA, and other compounds, buoyed by positive trial results and regulatory efforts, but faces challenges like insurance coverage and regulatory navigation; several companies eye rapid development under FDA fast-track programs as the psychedelics market aims for widespread clinical use.

via CNBC|

#ataibeckley #business #fda-breakthrough-therapy-designation

business3 months ago•2 min saved

Lilly bets big on psychedelics with $2.8B AtaiBeckley deal

Eli Lilly agreed to acquire AtaiBeckley for $2.8 billion upfront to expand into psychedelic mental-health therapy, led by BPL-003 (intranasal 5-MeO-DMT) which showed phase 2b improvements in treatment-resistant depression; the deal includes up to $1 billion in contingent payments tied to milestones for VLS-01 and BPL-003, plus a $6.75-per-share price with a 40% premium, positioning Lilly to compete with J&J’s Spravato in the TRD market.

via Fierce Biotech|

#acquisition #ataibeckley #business

health3 months ago•7 min saved

Implantable Vagus Nerve Stimulator Delivers Lasting Relief for Severe Depression in US Trial

The US RECOVER trial of 493 patients with severe, treatment-resistant depression found that an implanted vagus nerve stimulator produced lasting benefits: 69% had meaningful improvement at 12 months, and over 80% of those continued to improve or stay improved at 24 months; among strong early responders (50%+ symptom reduction), 92% remained improved at two years, and about one-third of initial non-responders improved by 24 months. While not a rapid fix and not universal in effect, the durable benefits (funded by device maker LivaNova) could influence coverage decisions for VNS as a treatment option.

via ScienceAlert|

#clinical-trial #depression #health

health6 months ago•9 min saved

Brain Pacemaker Trials Offer Hope for Treatment-Resistant Depression

About 30% of people with depression do not respond to standard treatments. Researchers are testing deep brain stimulation (DBS) as a potential option, delivering electrical pulses via implanted electrodes to the brain’s white matter to gradually help escape a depressive state. DBS for depression is not FDA-approved and is available only in clinical trials, including UT Southwestern and the TRANSCEND study. Eligibility typically includes major depressive disorder with multiple failed treatments. If results are positive, FDA approval could come within several years, expanding options beyond ECT, TMS, and ketamine.

via Neuroscience News|

#clinical-trials #deep-brain-stimulation #health

health8 months ago•6 min saved

Psilocybin-based therapy shows rapid relief in treatment-resistant depression, eyeing FDA approval

Compass Pathways reported two positive late-stage trials of a synthetic psilocybin treatment that rapidly reduces symptoms in patients with treatment-resistant depression, potentially becoming the first psychedelic medicine to gain full regulatory approval if the FDA approves it early next year.

via The Economist|

#compass-pathways #depression #fda

health8 months ago•12 min saved

The Elusive Fit: Why Antidepressants Don’t Work for Everyone

Antidepressants have helped some people for decades, but research shows they often provide only modest relief overall, with no reliable way to predict who will benefit. The history traces from iproniazid and imipramine to SSRIs and beyond, while meta-analyses indicate small improvements over placebo and low remission rates for many drugs. Ketamine offers rapid relief for some with treatment-resistant depression, challenging the idea that depression is a simple chemical imbalance. Precision psychiatry aims to tailor treatments via blood tests and genetic or neural markers, but this approach is still years away from routine practice. The field continues to wrestle with what depression actually is and how to best help the millions affected.

via The Dispatch|

#antidepressants #depression #health

health9 months ago•6 min saved

Implantable nerve stimulator delivers lasting relief for severe treatment-resistant depression

A multicenter trial shows an implanted vagus nerve stimulator can produce durable improvements in mood, quality of life, and daily functioning for severe treatment-resistant depression, with most gains persisting at two years and over 20% of participants in remission; some patients improved only after extended treatment, highlighting potential but ongoing barriers like cost and coverage.

via SciTechDaily|

#depression #health #long-term-outcomes

health9 months ago•323 min saved

Five-day brain-stimulation therapy sparks remission in some with treatment-resistant depression

A Stanford-led study tests SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy), a five-day, high-precision, noninvasive brain-stimulation treatment for treatment-resistant depression. In the trial, about half of the 24 participants receiving SAINT remitted by one month, compared with about 21% in the placebo group. SAINT uses rapid magnetic pulses targeted at the left dorsolateral prefrontal cortex via ten 10-minute sessions per day, delivering treatment faster and with greater precision than conventional TMS; the FDA cleared SAINT in 2022 and it’s offered at about 17 US clinics, though costs range roughly $16,000-$30,000 and insurance coverage varies. EEG data hint at biomarkers that could help predict who benefits, but more diverse studies are needed to confirm durability and broader applicability.

via CNN|

#depression #health #saint-therapy

health1 year ago•4 min saved

Innovative Brain Stimulation Offers New Hope for Depression Treatment

A 44-year-old man with 31 years of treatment-resistant depression experienced a significant and lasting improvement after undergoing personalized brain stimulation therapy called PACE, which tailored electrical stimulation to his unique brain activity, leading to an overwhelming feeling of joy and sustained mental health benefits over months.

via Indian Defence Review|

#brain-stimulation #depression #health

health1 year ago•8 min saved

Parents Explore Controversial Ketamine Therapy for Teens

Parents are increasingly turning to controversial ketamine therapy for their teens with severe mental health issues, despite limited research and potential risks, as a last resort after traditional treatments fail.

via USA Today|

#health #ketamine-therapy #mental-health-controversy

health1 year ago•3 min saved

Brain Stimulation and Implants Revolutionize Mental Health and Pain Treatment

A man with severe, treatment-resistant depression experienced joy for the first time in decades after a personalized brain stimulation treatment targeting specific brain networks, leading to sustained remission for two years. The approach involves precise electrode implantation and adjustable stimulation based on patient feedback, representing a promising advancement in psychiatric treatment.

via Gizmodo|

#brain-stimulation #depression #health

business1 year ago•11 min saved

Compass Psilocybin Achieves Key Phase 3 Success in Depression Treatment

Compass Pathways' Phase 3 trial of its synthetic psilocybin, COMP360, showed a significant separation from placebo in treating treatment-resistant depression, with no new safety concerns, marking a major milestone for psychedelic drug development. The company is now focusing on a larger, multi-dose trial expected to provide clearer efficacy data and aims for FDA submission, while preparing for potential U.S. market launch.

via Psychedelic Alpha|

#business #compass-pathways #phase-3-trial